Clinical trial
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III…
NCT00003095 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00003095 |
|---|---|
| Title | S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer |
| Official title | S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623 |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Study type | Observational |
| Conditions | Breast Cancer |
| Enrollment | 26 |
| Start date | Nov 1, 1997 |
| Primary completion | Feb 1, 2001 |
| Completion | Feb 1, 2001 |
| First posted | May 19, 2004 |
| Last update posted | Oct 26, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: